TY - JOUR
T1 - Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia
T2 - A prospective, multicenter study of 91 episodes
AU - Muder, Robert R.
AU - Harris, Ann P.
AU - Muller, Sharon
AU - Edmond, Michael
AU - Chow, Joseph W.
AU - Papadakis, Konstantinos
AU - Wagener, Marilyn W.
AU - Bodey, Gerald P.
AU - Steckelberg, James M.
PY - 1996
Y1 - 1996
N2 - We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94% of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21%. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.
AB - We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, had received immunosuppressive therapy, and had indwelling venous catheters. Although 94% of patients received an antimicrobial agent to which the blood isolate was susceptible, the mortality among these patients 14 days after the onset of bacteremia was 21%. Mortality was significantly correlated with the presence of a hematologic malignancy or neutropenia or transplantation, immunosuppressive therapy, and a severity-of-illness score of >4. S. maltophilia infection is associated with substantial morbidity and mortality among highly compromised patients. The organism is typically resistant to expanded spectrum β-lactam agents and aminoglycoside antibiotics. Trimethoprim-sulfamethoxazole should be administered if the isolate is susceptible to this combination; addition of another agent to which the isolate is susceptible should be considered in treating patients who are neutropenic, immunocompromised, or critically ill.
UR - http://www.scopus.com/inward/record.url?scp=0029782406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029782406&partnerID=8YFLogxK
U2 - 10.1093/clinids/22.3.508
DO - 10.1093/clinids/22.3.508
M3 - Article
C2 - 8852971
AN - SCOPUS:0029782406
SN - 1058-4838
VL - 22
SP - 508
EP - 512
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -